The OECI is a network of cancer institutes which aims to improve the quality of cancer care and translational research in Europe from an organisational viewpoint. Although physicians, nurses and researchers, constitute the core of cancer care and research, a smooth organisation, efficient logistics and state of the art complex infrastructure is needed to accelerate the production and application of personalised care approaches: the comprehensive cancer centre. A strong organisation of cancer institutes at a European level, such as OECI, is needed to contribute to the diffusion of knowledge on the quality of organising cancer care and translational research.

The OECI is a continuously developing network, presently regrouping 70 cancer centres and institutions across Europe. The OECI is working dynamically in crosscut expertise projects organised by involving the OECI Working Groups, activities and Members. Currently, there are 6 main Working Groups and 2 Activities which develop tools and programmes that can assist in improving cancer care through education, quality improvement, production of options and recommendations, standardising the molecular pathology approaches.

OECI cooperates with representative professional organisations at a European level and investigates possibilities to team up with its American counterpart, the American Association of Cancer Institutes. It aims to improve the quality of care and of the research at a European level also in collaboration with the European Commission with a bottom up approach. With various countries we explore the possibility to transfer at national level tools developed thanks to a European cooperation and which could be tailored for national use, such as the OECI accreditation and designation system.

The OECI is also exploring how to facilitate the interaction among national cancer coordinating bodies and authorities to facilitate the possible transfer of already tested organisational practice and check the feasibility to extend their applications at more wide European level.

The 2013 Oncology Days, organised in conjunction with the 2013 Annual General Assembly, aim to improve the role of the Organisation in supporting the coordination role that Europe needs to reduce fragmentation, to give the possibility to all the cancer patients to receive the best cures and to evaluate the costs-benefits linked with the application of new therapeutic approaches in order to avoid unnecessary care approaches.

We thank the local Organisers and in particular the UZVUB Oncologic Center and the Institut Jules Bordet which make possible the event.

Wim H. van Harten
OECI President
Host welcome

The pursuit of internationalisation policies is a must for Belgium. These policies are fundamental for the promotion of the European Research Area and for the development of translational processes. This makes possible to attract the interest of the whole sectors and invest in younger generations in order to further enhance the Belgian scientific expertise.

Knowledge and Innovation are at the centre of the Horizon 2020 strategy, which sets as main goals the strengthening of the EU's position in science in order to provide a boost to top-level research in Europe, the strengthening of industrial and academic leadership in innovation with more investments in key technologies, greater access to capital and support for SMEs and Universities.

Horizon 2020 will tackle societal challenges by helping to bridge the gap between research and the market, taking into account the added value of a dynamic independent academic research. This approach will include creating partnerships with the private sector, Universities and Member States in order to bring together the needed resources.

Since the OECI offers to the major European Cancer Institutes and to the whole cancer community an opportunity to meet, exchange ideas and assess outcomes, this is perfectly in line with the Horizon 2020 strategy and the goals to be achieved in the following years.

At the same time, the Organisation acts as an ideal context in which experts can join together in order to rapidly achieve objectives to improve early prevention, detection, a more accurate diagnostic approach and personalized therapies.

In stressing once again the importance of the OECI annual meeting as a tool to further strengthen the interaction among European stakeholders, we would like to thank all speakers and moderators that will contribute to the event. We hope the "OECI 2013 Oncology Days" proudly hosted by Belgium, will achieve its objectives.

---

Dominique De Valeriola  
Medical Director Institute Jules Bordet

Jean Benoit Burrion  
Deputy Medical Director Institute Jules Bordet

Mark De Ridder  
Head Dpt. Radiation Oncology UZBrussel

Frans Keuppens  
President OC UZBrussel

Guy Storme  
OECI Executive Secretary

Claudio Lombardo  
OECI Director
Introduction to the OECI

The OECI is a non-government Organisation founded in Vienna in 1979. The primary objectives of its 70 Members are to improve communication and to increase collaborative activities among European cancer institutes. The Members collaborate dynamically with the 6 OECI Working Groups and the 2 Activities - http://www.oeci.eu/WorkingGroupsMW.aspx

The OECI goals are achieved by promoting and strengthening Comprehensive Cancer Centres in Europe in order to reduce cancer incidence and mortality, and to improve quality in cancer care and translational research also from an organisational viewpoint. In order to facilitate the activities of their members and the definition of common programs of international interest, and to facilitate the participation in European projects and programs, in 2005 the OECI was remodelled into a European Economic Interest Grouping, becoming the OECI-EEIG.

To better contribute to the increase of the quality of care, the OECI has the objective to include within 2014 into the Accreditation/Designation program, 50% of its members.

In view of the crucial role of the pathology departments in oncology and of the expected “flood” of new markers and diagnostics, the OECI acts in close cooperation with the EurocanPlatform and the EACR in order to strengthen and disseminate the innovation process among its members.

In view of the huge number of cancer survivors, partly due to increasing success rates of treatments, the OECI stimulates a better cooperation on survivorship management which is specifically multidisciplinary for its nature.

The educational activities take especially place in the above mentioned fields in order to strengthen the aims of the OECI and disseminate the generated knowledge.

The managerial support is mainly organised through the Office of the President in Amsterdam, the Central Office in Brussels, and the Liaison Office in Genoa. Regular updating and reports of the OECI activities appear on the oeci@oeci.eu website and through ecancermedicalscience, the official OECI e-Journal.

Accreditation and Designation

The Accreditation/Designation WG (A&D) aims at defining consensual European quality standards and criteria supporting the concept of Comprehensive Cancer Centres with integration of care, research and education. The WG developed a tool for professionals enabling the performances of cancer institutes to be assessed both internally and externally. In order to increase the efficacy of cancer research and to strengthen joint public/private research in Europe for more competitive cancer research, thanks to the A&D WG, the OECI is producing a database of cancer centres detailing the available infrastructures and human resources in order to allow the identification of the structures where accelerated development of innovative treatments or high-quality clinical research is feasible. One of the main goals of the A&D WG is the establishment of criteria for European Comprehensive Cancer Centres and the harmonisation of their resources in order to reach a critical mass for research.

Starting from June 2012, the OECI Accreditation and Designation system is also open to non-OECI members. For more details contact oeci@oeci.eu
Biobanks and Molecular Pathobiology
The Biobanks and Molecular Pathobiology WG (BAMP) aims at promoting new developments in histopathology, cytology and molecular testing applying new updated tumor classifications and prognostic criteria based on modern technologies such as molecular testing. The WG focuses on education, training and on the optimal organisation in Cancer Institutes involving young pathologists and molecular biologists, as well as on providing support for staff members in less developed areas, which need to be updated on these new approaches in cancer diagnosis including sample collection and storage. Regular annual meetings are organised with the support of OECI Cancer Centres and in conjunction with other European Cancer Societies. The WG wants to contribute to an efficient infrastructure for the OECI multi-centre research platforms, providing request options for samples collected from cancer patients for translational and clinical research to be used for cooperative multicentres research adopting agreed rules for access and exchange.

Communication and Dissemination
The Communication and Dissemination Activity (CADA) aims at facilitating exchanges between scientists and clinicians within the OECI Institutes, helping people working on common projects, on developing and sharing trial protocols, data, meta-analyses, more generally, any activity which needs connectivity and communication. The Activity is developed in connection with eCancermedicalscience, the official Journal of the OECI and in which web visitors can read on science and watch videos from 203 countries connecting on eCancer.eu. This Activity aims also at better disseminating the initiatives of the OECI Members, WGs and Activities through the publication of leaflets illustrating the OECI as a whole as well as the single initiatives. As a registered Publisher, the OECI produced specific titles downloadable at www.oeci.eu/Publications.aspx.

Cost-Benefit – Health Economics
The OECI is proud to announce the constitution of a Cost-Benefit (COBE) Working Group that will facilitate careful and explicit balancing of clinical benefits and financial impact of cancer treatments. The primary objectives of the WG will be to demonstrate remits of cost-benefit analyses in oncology and to establish standards in budget impact analysis for OECI members. The WG will also pay attention to those recent developments in health economics, for example value based pricing, budget impact expertise, which have the special interest of the members. An interest call will be sent out soon to all members for their input. The OECI welcomes Dr. Lotte Steuten to whom the coordination of the new WG has been assigned.

Education and training
The Education and Training WG (ETWG) aims at coordinating and implementing the educational activities of European Cancer Institutes by promoting the establishment of a European Area for E&T in oncology, and by stimulating tighter relationships among OECI members, while defining a better connection with external bodies, such as the European School of Oncology, EACR, ECCO and ESMO, among others. Through the ETWG’s plan of activities, the OECI helps in finding practical solutions following the Lisbon goals, tackling
fragmentation in training, sharing knowledge and facilities among CCCs, facilitating the launch of new research initiatives, reinforcing existing successful actions, improving knowledge on new emerging fields and exchanging personnel with industries and vice-versa. In the coming years the educational programme is planning to increase the involvement of emerging countries by encouraging them with at least one significant event they will host. This will amplify the cooperation among all countries in Europe.

**Eurocan Platform**
The **EurocanPlatform WG (EP)** is a NoE of European Comprehensive Cancer Centres recently financed by the EC within the 7FP; through membership and personal involvement, it is closely linked to the OECI.
The EurocanPlatform works towards the decreasing of cancer mortality by cooperation of major Comprehensive Cancer Centres and is aiming to bring translational research results to a new level. It connects the necessary resources and provides know-how for the entire research continuum: basic research, early and late translational research, clinical research, epidemiological research, implementation in care and population based outcome research. A strong focus is related to discovery-driven translational cancer research in five selected tumours: breast, head-neck, lung, malignant melanoma and pancreatic cancer. Joint structures and programmes for early detection contribute to optimal treatment, while novel prevention research programmes will integrate prevention activities in clinical cancer centres as well as public prevention.

**Prevention and Early Diagnosis**
The **OECI WG on Cancer Prevention and Early Diagnosis (CPED)** explores the following objectives:
- to foster links with and influence other European activities concerned with cancer prevention;
- to develop additional standards on cancer prevention for consideration by the OECI designation and accreditation programme;
- to survey current levels of service, educational and research activities relating to cancer prevention and early detection among OECI members;
- to provide a mechanism for the development of prevention research collaborations between OECI member organisations and to secure the necessary funding.

**STARTActivity**
The **START-OECI Activity** is an evidence-based “state of the art” instrument on cancer diagnosis and treatment, created to support oncologists and physicians in their everyday oncology practice. In order to provide more comprehensive care and improve patients’ quality of life through an evidence-based medicine, START-OECI works according to a consistent methodology, whereby each chapter results from a definite, internal collaborative process. The chapter is published online and in Critical Reviews in Oncology and Haematology as well as in specific series of Volumes which are published directly by the OECI. The first volume can be downloaded from www.oeci.eu. About 30% of the START Contributors belong to OECI Members or Associate Members.
# The OECI board

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Wim H. van Harten</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Past President</td>
<td>Marco A. Pierotti</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Executive Secretary</td>
<td>Guy Storme</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>Treasurer</td>
<td>José Maria Laranja Pontes</td>
<td>Porto, Portugal</td>
</tr>
<tr>
<td>Elected Member</td>
<td>Julio Celis</td>
<td>Copenaghen, Denmark</td>
</tr>
</tbody>
</table>

# Co-opted Members

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accreditation and Designation</td>
<td>Mahasti Saghatchian</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Biobanks and Molecular Pathobiology</td>
<td>Giorgio Stanta</td>
<td>Trieste, Italy</td>
</tr>
<tr>
<td>Communication and Dissemination</td>
<td>Gordon McVie</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Cost - Benefit</td>
<td>Lotte Steuten</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Education &amp; Training</td>
<td>Angelo Paradiso</td>
<td>Bari, Italy</td>
</tr>
<tr>
<td>EurocanPlatform</td>
<td>Ulrik Ringborg</td>
<td>Stockholm, Sweden</td>
</tr>
<tr>
<td>START-OECI</td>
<td>Lisa Licitra</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Prevention and Early Diagnosis</td>
<td>Pending</td>
<td></td>
</tr>
</tbody>
</table>
The OECI is a cancer network, presently regrouping 70 cancer centres and institutions across Europe. The OECI is dynamically working in crosscut expertise projects organised by involving the OECI Working Groups, Activities and Members. Currently, there are 6 main Working Groups and 2 Activities.
The OECI membership

Austria
- Comprehensive Cancer Center Vienna
  Vienna
Belgium
- Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles
  Brussels
- Oncology Centre UZ Brussels
  Brussels
- Cliniques Universitaire Saint-Luc
  (Centre du Cancer), Brussels

Czech Republic
- Masaryk Memorial Cancer Institute
  Brno

Denmark
- Danish Cancer Society, Institute of Cancer Biology
  Copenhagen

Estonia
- North Estonia Medical Centre
  Tallinn
- Tartu University Hospital
  Tartu

Finland
- Helsinki University Central Hospital
  Helsinki

France
- Centre Alexis Vautrin
  Nancy
- Centre G.F. Leclerc
  Dijon
- Centre Leon Berard
  Lyon
- Centre Paul Strauss
  Strasbourg
- Institut Curie
  Paris
- Institut Gustave Roussy
  Villejuif
- Centre Henri Becquerel
  Rouen
- Centre Paul Papin CRLCC
  Angers
- Institut Sainte Catherine
  Avignon
- Institut Claudius Regaud
  Toulouse

Germany
- Deutsches Krebsforschungszentrum
  Heidelberg
- University Cancer Centre Dresden
  Carl Gustav Carus
  Dresden
- Charité Comprehensive Cancer Center
  Berlin

Greece
- Agii Anargiri General Oncological Hospital of Kifissia
  Athens

Hungary
- National Institute of Oncology
  Budapest
- National Koranyi Institute of TB and Pulmonology
  Budapest

Italy
- Azienda Ospedaliera Arcispedale S. Maria Nuova, Reggio Emilia
  Reggio Emilia
- Centro di Riferimento Oncologico (CRO) Istituto Nazionale Tumori
  Aviano
- European Institute of Oncology (IEO)
  Milan
- European School of Oncology (ESO)
  Milan
- Fondazione IRCCS Istituto Nazionale Tumori (INT)
  Milan
- Fondazione San Raffaele
  Milan
- IST Istituto Nazionale per la Ricerca sul Cancro
  Genoa
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione ‘G. Pascale’
  Naples
- Istituto Regina Elena (IRE)
  Rome
- Istituto Superiore di Oncologia (ISO)
  Genoa
- Istituto Tumori Giovanni Paolo II
  Bari
- Istituto di Ricerche Farmacologiche Mario Negri IRFMN
  Milan
- Istituto di Ricerca e Cura del Cancro di Candiolo
  Turin
• Istituto Oncologico Veneto (IOV) Padua
• Istituto FIRC di Oncologia Molecolare (IFOM) Milan
• Centro di Riferimento Oncologico della Basilicata (CROB) Potenza
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Meldola - Forlì

Lithuania
• Institute of Oncology, Vilnius University Vilnius

Norway
• Rikshospitalet-Radiumhospitalet Medical Center Oslo

Poland
• Wielkopolskie Cancer Centre Poznan

Portugal
• Instituto Portugues de Oncologia Francisco Gentil EPE do Porto Oporto
• Instituto Portugues de Oncologia Francisco Gentil EPE do Coimbra Coimbra
• Instituto Portugues de Oncologia Francisco Gentil EPE do Lisboa Lisbon

Romania
• Oncology Institute ‘Prof. Dr. Ion Chiricuta’ Cluj-Napoca
• Institute of Oncology ‘Prof. Dr. Al Trestioreanu’ Bucharest

Russia
• Biokhin Russian Cancer Research Centre Moscow
• Clinical Cancer Centre Kazan

Serbia - Montenegro
• Institute of Oncology Sremska Kamenica Novi Sad Sremska Kamenica

Slovakia
• Slovak Comprehensive Cancer Centre Bratislava

Slovenia
• Institute of Oncology Ljubljana Ljubljana

Spain
• Centro Nacional de Investigaciones Oncologicas Madrid
• Institut Català d’Oncologia Barcelona
• Instituto Madrileno de Oncologia (IMO) Madrid
• Fundacion Instituto Valenciano de Oncologia (IVO) Valencia

Sweden
• Salgrensska University Hospital Göteborg
• The Karolinska University Hospital and Institute Stockholm

The Netherlands
• Erasmus MC Daniel den Hoed Cancer Centre Rotterdam
• Integral Kankercentrum Noord-Nederland Groningen
• The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam
• Maastricht University Medisch Centrum Maastricht

Turkey
• Dokuz Eylül University Institute of Oncology Izmir

Ukraine
• R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology Kiev

United Kingdom
• Cancer Research UK Cambridge Research Institute London
• Christie Hospital NHS Foundation Trust Manchester
• King’s Health Partners Integrated Cancer Centre London

THE OECI MEMBERSHIP
Pride in its past, focused on the future
For over 70 years, the Jules Bordet Institute has been providing its patients – and the general public – with a wide range of state-of-the-art strategies for dealing with cancer. The Institute, which is an academic one, combines three essential missions: treatment, research and teaching. Its international reputation draws talented people to the Institute, who discover an environment conducive to fulfilling their human and professional qualities. Driven by a spirit of innovation, the Institute has continuously participated in the development of new diagnostic, therapeutic and preventive techniques, which are quickly made available to the public.

International collaborative research
Patient-oriented research includes the 120 clinical studies vetted by the Institute’s Ethics Committee, on which patients are represented, as well as the activities of 5 translational and basic research laboratories. Aware as it is of the challenges of research, the Institute has participated in the creation of several international networks: the European Organisation for Research and Treatment of Cancer (EORTC), the Multinational Association of Supportive Care In Cancer (MASCC), the Breast International Group (BIG), the European Lung Cancer Working Party (ELCWP), and the Organisation of European Cancer Institutes (OECI).

A Comprehensive Cancer Center
Research activities coexist with teaching, with both being closely associated with care and treatment. Physicians in the various diagnostic and therapeutic disciplines, nurses, and other healthcare professionals work closely together in a structure organised around the well-being of the patient. The Institute provides an exhaustive scope of services to its patients, from primary prevention to physical and psychological rehabilitation, encompassing relatives and taking into account socio-economical parameters.
Quality oriented
Awarded with the OECI Accreditation label, the Institute carries out a global quality management policy, with specific attention paid to certain areas: radiotherapy, nuclear medicine, transplantation in haematology, clinical biology, pathology and molecular biology laboratories.

New Bordet in 2018
The Institute is part of the public hospitals network in Brussels (IRIS) and the Université Libre de Bruxelles. With its 154 beds entirely devoted to cancer treatment, every year, it looks after 6,000 hospitalised patients, carries out 75,000 consultations, and provides over 12,000 outpatient treatments. To respond adequately to the demographic, epidemiological and scientific developments of the future, it plans to move to new facilities in 2018, thereby increasing its hospital-bed capacity to 250.

Our teams are entirely engrossed in their missions and put respect for human life beyond other considerations. The Institute is above all a point of contact between caregivers and patients. They share a project: to see that life wins out, by jointly taking on the multiple incertitudes of the medical art in which they have put their hopes.

www.bordet.be

Dominique De Valeriola
Medical Director
Institute Jules Bordet

Jean Benoit Burrion
Deputy Medical Director
Institute Jules Bordet
The Oncology Center UZ Brussel (OC UZ Brussel), was founded in 1975. The initial goals of the Center were to establish a multidisciplinary model of cancer care in a united geographical structure, establish original research lines and create a “bench to bedside and back” environment. In addition the center was to establish a faculty for teaching the various aspects of cancer in cooperation with the faculty of medicine of the VUB. This concept corresponded to the criteria of a Comprehensive Cancer Centre as defined in 1984.

The center has achieved these initial goals and expanded them much further. Today the Center and its staff have a strong national and international profile and a leading role in key development areas of oncology: image-guided radiotherapy (IGRT) linked with intensity modulated radiotherapy (IMRT) and tracking of moving targets to increase local cure with less toxicity; a stem cell transplantation unit and multiple myeloma center with a unique preclinical model with a high translational value; genomic driven targeted therapies in lung cancer, melanoma and brain tumors; a familial cancer clinic and related clinical and genomic research; an extensive melanoma therapeutic vaccination program, a breast center with lymphedema research; imaging research and a cancer prevention unit.

Teaching not only encompasses undergraduate and graduate teaching to physicians and nurses, but also postgraduate courses in immunology of cancer, hematology and molecular targets in cancer and medical oncology with participation of national faculty.

The center has a specific clinical and research program in cancer in the elderly and in survivorship with a program of comprehensive revalidation and rehabilitation.
This therapeutic and research effort is complemented by a strong supportive and palliative unit that also runs a day-care facility. There is extensive research in end-of-life issues. These activities of the center have an important societal impact, including the creation of legislation regarding end-of-life issues.

All of these activities have built national and international networks of collaboration, including with the EORTC.

The OC UZ Brussel has contributed to the establishment of the National Cancer Plan and is active in various aspects of its execution.

The center hosts foreign nationals as students in the clinic and research.

A major current focus is the establishment of personalized medicine through a dedicated effort in tumor banking and the establishment of an advanced Next Generation Sequencing platform and bioinformatics.

The OC UZ Brussel is a member of the Organization of European cancer Institutes (OECI) since 1991 including the presidency from 1999 till 2002 and is currently pursuing an accreditation from the OECI and ESMO.

Mark De Ridder  
Head Dpt. Radiation Oncology  
UZBrussel

Frans Keuppens  
President OC  
UZBrussel
The OECI 2013 Oncology Days

On May 13-16 2013, Brussels hosts the OECI European Oncology Days including several scientific events aiming to create an opportunity to focus on specific issues of great interest for cancer innovation.

The OECI 2013 Oncology Days include:

May 13th afternoon
- OECI Extended Board (restricted to Extended Board members)
- Joint Meeting OECI Board-Accreditation and Designation Board (restricted to Boards Members)

May 14th morning
- The Bench-Can Project - Core Group Meeting
- Press conference Oncology Days
- The EurocanPlatform Network of Excellence Symposium

May 14th afternoon
Parallel Symposia
- Cancer Education and Training in Central and Eastern (CE) European Countries: OECI and EurocanPlatform perspectives
- Quality of Comprehensive Cancer Centres and accreditation development

May 15th morning
OECI 2013 General Assembly – Administrative Session (restricted to OECI Members)

May 15th afternoon
Satellite Symposia
- National Programs for Translational Cancer Research and Translational Oncology
- Personalised and Sustainable Oncology Care: health economic perspectives

May 16th
OECI Molecular Pathology Day Symposium

Social events (restricted to OECI Members)

May 14th afternoon
Brussels City Hall welcome cocktail and Award of the OECI 2013 Cancer Prize - in the presence of Her Royal Highness Princess Astrid

May 14th evening
OECI 2013 Gala Dinner - Restaurant “La Maison du Cygne”
MORNING SESSION

9.00 – 11.00
The Bench-Can Project
Core Group Meeting
(Restricted to the Partners)
Gengou Auditorium

10.00 – 11.00
Press conference Oncology Days
Tagnon Auditorium

11.00 – 11.15
COFFEE BREAK

A strategic collaboration to sustain innovation in Comprehensive Cancer Centres

The EurocanPlatform Network of Excellence
Tagnon Auditorium
Chair: Ulrik Ringborg and Wim H. van Harten

11.15
Introduction
Ulrik Ringborg

An update on Horizon 2020: work in progress
Jan van de Loo

Early detection and biomarker discovery
Marco Pierotti

Other strategic research activities
Ulrik Ringborg

Biobanking
Maria Grazia Daidone

Education
Angelo Paradiso

Communication and dissemination
Gordon McVie

Sustainability of the EurocanPlatform consortium
Julio Celis

13.00 LUNCH
AFTERNOON SESSION
Parallel Symposium 1

Cancer Education and Training in Central and Eastern (CE) European Countries: OECI and EurocanPlatform perspectives

Chairpersons: Alberto Costa and Angelo Paradiso

14.00: ESO activities overview in CE European Countries
Alberto Costa

OECI education and training programme for CE European Countries
Angelo Paradiso

Cancer education in Lithuania
Ernestas Janulionis

Cancer education in Ukraine
Vasyliy F. Chekhun

European training and mobility opportunities for oncologists
Bodo Richter

Parallel Symposium 2

Quality of Comprehensive Cancer Centres and accreditation development

Chairpersons: Alberto Costa and Mahasti Saghatchian

14.00: OECI Accreditation and Designation Programme: Report of a 10-year experience dedicated to cancer centres
Mahasti Saghatchian

Health technology assessment, Dutch experience
Melvin Kilsdonk

OECI-ESO-DKG Prostate Cancer Units Initiative in Europe
Riccardo Valdagni

European Commission Breast Cancer Accreditation Services
Donata Lerda

Across the channel, the United Kingdom vision of quality and outcome needs
Chris Harrison

Accreditation, why? Future European perspectives in the following years
Thomas Tursz
GENERAL ASSEMBLY

8.30 Registration

8.50 General Assembly constitution and President addresses

9.00 Session 1: Administrative and financial matters
Chairpersons: Wim H. van Harten and Guy Storme

Point 1: Welcome and approval of the Agenda
Wim H. van Harten

Point 2: Approval of May 5th 2012 General Assembly's Minutes
(vote requested – decision taken at the simple majority of the votes
of the OECI full members present or represented)
Wim H. van Harten

Point 3: Approval of the Financial Statement 2012
(vote requested – decision taken at the simple majority of the votes
of the OECI full members present or represented)
Guy Storme and José Laranja Pontes

Point 4: 2013 and 2014 Provisional Budget
(only for 2013 vote requested – decision taken at the simple majority
of the votes of the OECI full members present or represented)
José Laranja Pontes

Point 5: OECI Board composition and election of two Members
Wim H. van Harten

Point 6: OECI Membership

6.1 New applications for membership and request of 1 Full Member
to become Associated Member

6.2 Proposal for discontinuing from the membership of OECI debtors
members (vote requested – decision taken at the unanimity of the
votes of the OECI full members present or represented)
Claudio Lombardo

THE ACCREDITATION EVALUATION REPORT
Mahasti Saghatcian
With the participation of Tom Hudson
Ceremony for the delivery of the OECI European
Accreditation Certificate to:
Institut Jules Bordet, Brussels, Belgium
Cambridge Cancer Centre, United Kingdom
Institut Gustav Roussy, Villejuif, France
Institute of Oncology, Vilnius University, Lithuania
Wim H. van Harten
11.15 COFFEE BREAK

11.30 Session 2: The OECI Program for the coming years
Chairpersons: Wim H. van Harten and Marco Pierotti

Point 7: The OECI 2013-2014 Program of activities

7.1 Introduction
Wim H. van Harten

7.2 Summary of the WG's activities
Marco Pierotti

7.3 Benchmarking comprehensive cancer care that provides interdisciplinary treatment for patients, and yield examples of best practice in comprehensive cancer care. OECI Project approved by the General Direction SANCO of the European Commission
Wim H. van Harten

7.4 EurocanPlatform NoE update
Ulrik Ringborg

Point 8: Venues of the General Assemblies for the coming years
Wim H. van Harten

13.00 LUNCH
FORUM

National Programs for Translational Cancer Research and Translational Oncology
Chairpersons: Fabien Calvo and Guy Storme

14.00: Introduction
Chairpersons

14.20: The Belgium National Cancer Program
Regine Kiasuwa Mbengi

14.40: The Italian Cancer network “Alleanza Contro il Cancro”
Marco A. Pierotti

15.00: The INCA (French Program for Translational Cancer Research)
Frédérique Nowak

15.20: Coordinating Cancer Research in the UK
Jane Cope

15.40: The Portuguese Cancer Network “Francisco Gentil”
José Laranja Pontes

16.20: Coordinating Cancer Research in Europe: ECCO’s role
Ulrik Ringborg

17.00 DISCUSSION AND CLOSING REMARKS

SATELLITE SYMPOSIUM

Personalised and sustainable oncology care: health economic perspectives
Chairperson: Lotte Steuten

Delivering sustainable and cost-effective oncology care
Richard Sullivan

Impact of technology on health care and cost-effectiveness of molecular imaging in oncology
Andrea Ciarmiello

Health economics and patient outcome evaluation in comprehensive cancer centres
Scott Ramsey

Personalised oncology care: including patient preferences in health economic evaluation
Maarten IJzerman

Health economic consequences of evolving radiation technologies and practices
Yolande Lievens
SATELLITE SYMPOSIUM

OECI Molecular Pathology Day

Chairpersons: Fatima Carneiro and Giorgio Stanta

9.00: Relevance of Archive Tissues in Modern Pathology
Giorgio Stanta

9.30: Biological Therapy Resistance
Raffaella Sordella

10.15: Discussion

10.30: COFFEE BREAK

Recent Approaches and Perspectives in Cancer Molecular Diagnostics

Chairpersons: Paul Span and Gerald Hoefler

11.00: Breast
Anna Sapino

11.30: Discussion

11.40: Colon
Andreas Jung

12.10: Discussion

12.20: Lung
Erik Thunnissen

12.50: Discussion

13.00: Standardization in Molecular pathology with regards to fully automated extraction of DNA and RNA for predictive tissue based oncology
Guido Hennig

13.10: LUNCH

OECI New Biomarker Validation Proposals

14.30: Chairpersons: Erik Thunnissen and Roberto Salgado

- HPV in Head and Neck Tumours
  Nina Gale
- New Colon Biomarkers
  Giorgio Stanta
- New treatment subgroups in breast cancer
  Anna Sapino

Quality Assessment for Molecular Diagnostics in Archive Tissues (Round Table)

16.00: Chairpersons: Han van Krieken and Giorgio Stanta
Participants:
Gerald Hoefler
Roberto Salgado
Erik Thunnissen
Han van Krieken
Chairpersons and invited speakers

Fatima Carneiro, University of Porto, Portugal
Julio Celis, OECI - Danish Cancer Society, Institute of Cancer Biology, Copenhagen, Denmark
Vasyl F. Chekhun, R.E. Kavetsky Institute, Kiev, Ukraine
Andrea Ciarmiello, Sant’Andrea Hospital, La Spezia, Italy
Jane Cope, National Cancer Research Institute, London, United Kingdom
Alberto Costa, European School of Oncology (ESO), Milan, Italy
Maria Grazia Daidone, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Nina Gale, University of Ljubljana, Slovenia
Chris Harrison, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Wim H. van Harten, OECI - Nederlands Kanker Instituut (NKI), Amsterdam, The Netherlands
Guido Hennig, Siemens Healthcare Diagnostics Holding GmbH, Eschborn, Germany
Alberto Costa, European School of Oncology (ESO), Milan, Italy
Maria Grazia Daidone, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Nina Gale, University of Ljubljana, Slovenia
Chris Harrison, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Wim H. van Harten, OECI - Nederlands Kanker Instituut (NKI), Amsterdam, The Netherlands
Guido Hennig, Siemens Healthcare Diagnostics Holding GmbH, Eschborn, Germany
Tom Hudson, European Cancer Patients Coalition, Brussels, Belgium
Maarten Ijzerman, University of Twente, The Netherlands
Ernestas Janulionis, Oncology Institute Vilnius, Lithuania
Andreas Jung, Ludwig Maximilians University, Munich, Germany
Melvin Kilsdonk, Nederlands Kanker Instituut (NKI), Amsterdam, The Netherlands
Han van Krieken, Radboud University Nijmegen, The Netherlands
Donata Lerda, Joint Research Centre Ispra - European Commission, Italy
Lisa Licitra, OECI - Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Yolande Lievens, University Hospital of Gent, Belgium
Jan van de Loo, European Commission, Brussels, Belgium
Claudio Lombardo, OECI - SOSEurope, Brussels, Belgium
Regine Kiasuwa Mbengi, Belgian National Cancer Plan, Brussels, Belgium
Frédérique Nowak, Institut National du Cancer, Paris, France
Angelo Paradiso, OECI - Istituto Oncologico “Giovanni Paolo II”, Bari, Italy
Marco A. Pierotti, OECI - Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
José Laranja Pontes, OECI - Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal
Scott Ramsey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Bodo Richter, European Commission Brussels, Belgium
Ulrik Ringborg, EurocanPlatform - OECI - Karolinska Institute, Stockholm, Sweden
Mahasti Saghatchian, OECI - Institut Gustave Roussy, Paris, France
Roberto Salgado, Institut Jules Bordet, Brussels, Belgium
Anna Sapino, University of Turin, Italy
Raffaella Sordella, Cold Spring Harbor, NY, USA
Paul Span, Radboud University Nijmegen, The Netherlands
Giorgio Stanta, OECI - University of Trieste, Italy
Lotte Steuten, OECI - University of Twente, The Netherlands
Guy Storme, OECI - Oncology Centre UZ Brussel, Brussel, Belgium
Richard Sullivan, King’s College NHS Health Centre, London, United Kingdom
Erik Thunnissen, VU Medical Center, Amsterdam, The Netherlands
Thomas Tursz, EurocanPlatform, Paris, France
Riccardo Valdagni, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
# General timetable

<table>
<thead>
<tr>
<th>Time</th>
<th>13 May 2013</th>
<th>14 May 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MORNING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.00 - 11.00</td>
<td><em>The Bench-Can Project</em></td>
<td><em>MORNING SESSION</em></td>
</tr>
<tr>
<td></td>
<td>Gengou Auditorium</td>
<td>9.00 - 11.00</td>
</tr>
<tr>
<td>10.00 - 11.00</td>
<td><em>Press conference Oncology Days</em></td>
<td><em>The EurocanPlatform</em></td>
</tr>
<tr>
<td></td>
<td>Tagnon Auditorium</td>
<td>Network of Excellence</td>
</tr>
<tr>
<td>11.00 - 11.15</td>
<td><em>COFFEE BREAK</em></td>
<td><em>Chairs: Ulrik Ringborg and Wim H. van Harten</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tagnon Auditorium</td>
</tr>
<tr>
<td>11.15 - 13.00</td>
<td><em>The EurocanPlatform</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Network of Excellence</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Ulrik Ringborg and Wim H. van Harten</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tagnon Auditorium</td>
<td></td>
</tr>
<tr>
<td><strong>AFTERNOON</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00 - 19.30</td>
<td><em>OECI Extended Board</em></td>
<td><em>AFTERNOON SESSION</em></td>
</tr>
<tr>
<td></td>
<td>Tagnon Auditorium</td>
<td><em>Parallel Symposium 1</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.00 - 16.30</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Cancer Education and Training in Central and Eastern (CE) Europe</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>OECI and EurocanPlatform perspectives</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Chairs: Alberto Costa and Angelo Paradiso</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tagnon Auditorium</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Parallel Symposium 2</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.00 - 16.30</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Quality of Comprehensive Cancer Centres and accreditation development</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Chairs: Alberto Costa and Mahasti Saghatchian</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gengou Auditorium</td>
</tr>
<tr>
<td><strong>EVENING</strong></td>
<td></td>
<td><em>Brussels City Hall Reception</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>OECI Cancer Prize Ceremony</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Gala Dinner</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>15 May 2013</td>
<td>16 May 2013</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MORNING</td>
<td>8.30 - 13.00 OECI 2013 General Assembly (Administrative Session)</td>
<td>9.00 - 13.00 OECI Molecular Pathology Day Symposium</td>
</tr>
<tr>
<td></td>
<td>Chair: Win H. van Harten</td>
<td>Chair: Giorgio Stanta</td>
</tr>
<tr>
<td></td>
<td>Tagnon Auditorium</td>
<td>Tagnon Auditorium</td>
</tr>
<tr>
<td></td>
<td>Lunch</td>
<td>Lunch</td>
</tr>
<tr>
<td></td>
<td><strong>OECI 2013 General Assembly</strong></td>
<td><strong>OECI Molecular Pathology Day Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PARALLEL SESSION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14.00 - 17.00 Forum National Programs for Translational Cancer Research and Translational Oncology Chairs: Frédérique Nowak and Guy Storme Tagnon Auditorium</td>
<td>14.00 - 17.00 Symposium Personalised and Sustainable Oncology Care: health economic perspectives Chair: Lotte Steuten Gengou Auditorium</td>
</tr>
</tbody>
</table>

**OECI 2013 ONCOLOGY DAYS**
May 13th
20.00 hrs.

**Extended Board Dinner**
Restaurant “Les Brigittines”

(Restricted to OECI Board Members and Co-opted Members).

May 14th
18.30 - 20.00 hrs.

**Brussels City Hall**
Welcome cocktail

**OECI 2013 Oncology Price Ceremony**
*In the presence of* Her Royal Highness Princess Astrid

May 14th
20.30 hrs.

**Gala Dinner**
Restaurant “La Maison du Cygne”

(Restricted to OECI Members and invited persons - registration required)
General information about Brussels

AIRPORT AND TRANSPORTATION
Brussels International Airport
Belgium’s main airport is located in Zaventem, 12 km north of Brussels. From this airport, you can reach Brussels by train or bus. Taxis are also readily available. An average taxi ride to the centre of Brussels costs €40.

Brussels Charleroi-Sud Airport
This subsidiary airport is located 46 km South of Brussels and is similarly accessible by train, bus and taxi. An airport shuttle departs every 30 minutes from the airport to take passengers to the Brussels South railway station.

Taxi
If you want to take a taxi in Brussels there are several companies to choose from:
Autolux: +32 (0)2 411 12 21
Taxis Bleus: +32 (0)2 268 00 00
Taxis Orange: +32 ((0)2 349 43 43
Taxis Verts: +32 (0)2 349 49 49

CLIMATE
In May, you can expect an average low of 11 C, and an average high of 20 C. Bring your umbrella!

REGISTRATION FEES
Registration and attendance at the meeting is free. Coffee breaks and lunches are provided during the meeting.

CONGRESS-SPECIFIC INFORMATION
Language
The official language is English. No simultaneous translation in other languages will be provided during the sessions.

ACKNOWLEDGMENTS
The OECI 2013 Oncology Days are made possible thanks to the contribution of OECI, and to the generous support of the local Organisers:
THE OECI 2013 SCIENTIFIC COMMITTEE
President: Wim H. van Harten
Members: Marco A. Pierotti, Guy Storme, José Maria Laranja Pontes, Julio Celis, Ulrik Ringborg, Mahasti Saghatchian, Giorgio Stanta, Lotte Steuten, Angelo Paradiso, Claudio Lombardo

THE OECI 2013 LOCAL ORGANISING COMMITTEE
Jean Benoît Burrion
Mark De Ridder
Dominique De Valeriola
Claudio Lombardo
Guy Storme

OECI OFFICES
AMSTERDAM: Georgette van Velzen
BARI: Silvana Valerio, Caroline Oakley
BRUSSELS: Lutgarde D’Hauwers
GENOA: Sergio Bottero, Germana Gianquinto, Giorgia Pesce
GRONINGEN: Femke Boomsma, Henk Hummel
MILAN: Daniela Majerna
PARIS: Cécile Tableau
TRIESTE: Valentina Melita

OECI 2013 SECRETARIAT AND COORDINATING OFFICE
Claudio Lombardo - OECI Director
Tel: +32 2 512 01 46
Email: oeci@oeci.eu
www.oeci.eu

Attendance to the OECI Oncology Days is free. Those interested in participating should send an email to oeci@oeci.eu indicating full name, home institution and symposium to which they intend to register.